Evolocumab Phase 3 Cognitive Function Study Results Published in the New England Journal of Medicine
Cambridge Cognition and Amgen announce that the New England Journal of Medicine (NEJM) published results from the evolocumab cognitive function trial, which was conducted in a subset of patients enrolled in the randomized, placebo-controlled evolocumab cardiovascular outcomes study.
CANTAB assessments used in EBBINGHAUS cognitive function trial for Amgen's evolocumab
Cambridge Cognition today reports its involvement in Amgen's EBBINGHAUS study with full results being presented at the American College of Cardiology Annual Scientific Session on 18 March 2017.
Design and rationale of the EBBINGHAUS trial
The Journal Clinical Cardiology has published on the design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo controlled, multicenter study to assess the effect of the human anti-PCSK9 monoclonal antibody evolocumab on cognitive function in patients with clinically evident cardiovascular disease receiving statin background lipid-lowering therapy1.